Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). Data were presented at The Liver Meeting® 2018 in San Francisco.
PSC is a rare, chronic condition that causes the network of ducts that drain bile from the liver to become inflamed and scarred over time. Progressive damage to the bile ducts in patients with PSC can lead to cirrhosis, liver failure, and cholangiocarcinoma (cancer of the bile ducts). Fatigue, pruritus and abdominal discomfort are common symptoms of PSC that can greatly impact patients’ quality of life. There are no approved treatments for PSC.
“Gilead is committed to applying our research expertise in liver disease to address this debilitating condition which may lead to serious liver-related complications for PSC patients,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. “These latest results from our Phase 2 program of GS-9674 are a positive step forward in the search for effective therapy.”
In the Phase 2, double-blind, placebo-controlled trial, 52 non-cirrhotic patients with PSC were randomized to receive GS-9674 100 mg (n=22), GS-9674 30 mg (n=20), or placebo (n=10) orally once daily for 12 weeks. After 12 weeks of treatment, patients receiving GS-9674 100 mg demonstrated significant improvements in liver biochemistry tests, with a median reduction in serum alkaline phosphatase (ALP) of 20.5 percent vs. an increase of 3.4 percent with placebo (p=0.029), median reduction in gamma-glutamyl transferase (GGT) of 30.3 percent vs. an increase of 1.1 percent with placebo (p<0.001), median reduction in alanine aminotransferase (ALT) of 49.4 percent vs. 12.9 percent with placebo (p=0.009), and a median reduction in aspartate aminotransferase (AST) of 42.3 percent vs. 10.8 percent with placebo (p=0.019). In both groups treated with GS-9674, reduced serum levels of C4, an intermediate in the synthesis of bile acids, were observed compared with placebo (-23.2 percent in the 100 mg group, p=0.21; and -30.5 percent in the 30 mg group, p=0.024). Reductions in serum bile acids were greatest with the 100 mg dose.
GS-9674 was well tolerated and the incidence of Grade 2 or 3 pruritus was numerically lower with GS-9674 100 mg (13.6 percent) and 30 mg (20 percent) compared with placebo (40 percent). There were no elevations in serum lipids. Treatment was discontinued due to adverse events in three patients treated with GS-9674 100 mg (14 percent), including one discontinuation due to pruritus, and one patient with placebo (10 percent).
A separate analysis of health-related patient-reported outcome measures (PROs) among patients enrolled in the Phase 2 trial demonstrated significant impairment of PRO scores among PSC patients with pruritus or fatigue. In the evaluation, patients treated with GS-9674 100 mg experienced significant improvement of the Primary Biliary Cholangitis – 40 (PBC-40) Emotional score (p=0.04) compared with patients treated with placebo.
“Patients living with PSC urgently need effective and tolerable treatment options,” said Michael Trauner, MD, presenting author and Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria. “These Phase 2 results are encouraging in terms of beneficial changes in liver biochemistry, markers of bile acid homeostasis, and patient-reported outcome measures. We look forward to further determining the safety and efficacy of this investigational agent.”
GS-9674 is an investigational compound and is not approved by the U.S. Food & Drug Administration (FDA) or any other regulatory authority. Its safety and efficacy have not been determined.
GS-9674 is an investigational, selective, non-steroidal agonist of the farnesoid X receptor (FXR), a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR is the primary regulator of bile acid synthesis and plays important roles in glucose and lipid metabolism. GS-9674 is being investigated for the treatment of PSC, primary biliary cholangitis (PBC), and advanced fibrosis due to nonalcoholic steatohepatitis (NASH), a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to scarring or fibrosis. GS-9674 is an investigational agent and its efficacy and safety have not been determined.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to complete the clinical trial programs evaluating GS-9674 for the treatment of primary sclerosing cholangitis in the currently anticipated timelines, or at all. In addition, there is the possibility of unfavorable results from additional clinical trials involving GS-9674. Further, it is possible that Gilead may make a strategic decision to discontinue development of GS-9674, and as a result, GS-9674 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Arran Attridge, 650-425-8975
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ABS, Google Cloud and SoftServe Partner to Demonstrate Feasibility of AI-enabled Corrosion Detection24.4.2019 15:57:00 CEST | Pressemelding
ABS, Google Cloud and SoftServe completed a pilot project applying artificial intelligence (AI) models to detect levels of corrosion and coating breakdown on ships and offshore structures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005822/en/ ABS, Google Cloud and SoftServe Partner to Demonstrate Feasibility of AI-enabled Corrosion Detection (Photo: Business Wire) The project successfully demonstrated the accuracy of AI in detecting and assessing structural anomalies commonly found during visual inspection. AI techniques could be further used to analyze images over time to understand corrosion and coating breakdown trends. “Digital innovation in AI will change how surveys and maintenance strategies are executed, driving more condition-based approaches to class and maintenance,” said ABS Chairman, President and CEO, Christopher J. Wiernicki. “We are building a future in which digital tools can remotely assess the co
The 2019 .eu Web Awards Launch Today24.4.2019 14:13:00 CEST | Pressemelding
The .eu Web Awards is an online competition designed to acknowledge the best websites using the .eu or .ею extensions in five diverse categories. Anyone who is eligible according to the .eu Web Awards rules can nominate their favourite .eu or .ею. website. This includes .eu and .ею domain name holders themselves, who can nominate their very own website for participation in the .eu Web Awards. “After the successful edition of 2018 with 130 nominations and nearly 10 000 votes for excellent sites, we look forward to awarding the best websites in the five categories”- Giovanni Seppia, EURid External Relations Manager. The 15 finalists will be invited to the .eu Web Awards gala in Brussels on 20 November 2019 where the five winners – one per category – will be announced. The winners will receive a prestigious award package, including a two-month billboard advertising campaign in Brussels Airport, a custom video produced by EURid for their promotional purposes, and a custom trophy and person
The Valence Group Advises INEOS on Its Sale of INEOS Melamines and Paraform to Prefere Resins Holding GmbH24.4.2019 13:54:00 CEST | Pressemelding
The Valence Group Advises INEOS Enterprises, a division of INEOS (“INEOS”), on its sale of INEOS Melamines and Paraform to Prefere Resins Holding GmbH. The Valence Group acted as financial advisor to INEOS Enterprises on its announced sale of INEOS Melamines & Paraform to Prefere Resins Holding GmbH. The agreement covers sites in USA, Germany and Indonesia. INEOS Paraform is Europe’s second largest producer of Paraformaldehyde. INEOS Melamines is a world leader in the supply of melamine resins into coatings, paper, textile, tyre, rubber, and decorative laminates industries. Financial terms of the transaction were not disclosed. About The Valence Group The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors. The Valence Group team includes a unique combination of professionals with backgrounds in investment banking and strategy consulting within the chemicals and materials ind
Centreon EMS Removes IT Monitoring Blind Spots between Hybrid, Multi-Cloud and Physical Networks24.4.2019 13:19:00 CEST | Pressemelding
Centreon, a trusted provider of enterprise monitoring solutions for converging and hybrid IT infrastructures, today rolled out a new release of Centreon EMS, its flagship, end-to-end IT monitoring platform. The new release provides ITOps with holistic and contextual insights, through the integrations needed for today’s distributed, on-premise and multi-cloud - public, private and container - environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005610/en/ Credits: GIF file of Centreon GeoViews. Centreon’s EMS 19.04 release offers ITOps managing a host of legacy assets but now contending with increased cloud workloads and growing networks of connected objects, the integrated visibility needed to ensure end-to-end performance across diverse IT environments. This expanded functionality reduces costs and complexity, aggregating data from across the entire IT infrastructure into a single, holistic view of the various
Neustar Research Shows Large Attacks Growing as Multi-Vector Exploits Increasingly Become the Norm24.4.2019 13:00:00 CEST | Pressemelding
Neustar, Inc., a trusted, neutral provider of real-time information services, today released its Q1, 2019 Cyber Threats and Trends report which highlights new areas of growth in Distributed Denial of Service (DDoS) attacks over the past year. The report affirms that DDoS attacks continue to be an effective means to distract and confuse security teams while inflicting serious damage to brands. The report reveals that while volumetric attacks over 50Gbps remain a relatively small segment of the overall threat picture at only 12% of attacks, their frequency has grown enormously when compared to the same period in 2018. The latest attacks morph over the course of the attack using a variety of ports and protocols to locate and exploit vulnerabilities. In Q1, 2019, over 77% of attacks used two or more vectors. In particular, the trend of targeting subnets and classless inter-domain routing (CIDR) blocks to slow or stop network traffic across the internet is a disruptive DDoS threat, identifi
Seoul Semiconductor Continues Enforcement against Infringement of Its LED Driver Patents24.4.2019 13:00:00 CEST | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it has filed another patent infringement lawsuit for infringement of its LED driver patents, this time against SATCO Products, Inc. (“SATCO”). In its complaint, Seoul asserts that SATCO is selling various LED lighting products that infringe “eleven” (11) of Seoul’s patents covering LED driver technology, including U.S. Patent 7,081,722, U.S. Patent 9,807,828; U.S. Patent 8,513,899; and U.S. Patent 8,716,946. The asserted LED driver patents are widely used in replacement bulbs in the form of incandescent or fluorescent lamps, wall-mount lights, and ceiling lights. The patented technology covers products with a linear driver for directly operating LEDs under household voltage, a step operation driver for generating flicker-free lights, as well as a dimmable driver for realizing smart lighting. Seoul has successfully enforced its LED driver patents in several